News
November 17, 2023
SOL-257 gene therapy improves outcomes in 2 ALS mouse models. Read more.
November 9, 2023
SOLA Biosciences Presents Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS, at Neuroscience 2023 and ALS One Symposium. Read more.
October 3, 2023
SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting. Read more.
April 2023
Series Pre-A+ Financing completed with UTEC
October 11, 2022
SOLA presented in ALS ONE Conference
September 22, 2021
ALS Association grant approved
The Amyotrophic Lateral Sclerosis Association and SOLA Biosciences entered a Research Grant Agreement to advance ALS animal efficacy studies of SOL-257.
September 9, 2021
Series Pre-A Financing completed with MP Healthcare Venture Management Inc. and Eisai Innovation Inc.
May 12, 2021
Featured in ASL News Today: Read more.
April 29, 2021
Presented at the 1st annual Muscular Dystrophy Association (MDA) Insights in Research Investor Summit
Positive data of animal efficacy study data of SOL-257 on the ALS/TDP43 mouse model was presented by Dr. Akinori Hishiya, CSO of SOLA Biosciences.
March 1, 2021
The Seed Financing by private investors completed
© 2021 SOLA Biosciences